Reduced intensity haplo plus single cord transplant compared to double cord transplant: Improved engraftment and graft-versus-host disease-free, relapse-free survival

Haematologica

Volumn 101, Issue 5, 2016, Pages 634-643

  van Besien, Koen ^a   Hari, Parameswaran ^b   Zhang, Mei Jie ^b   Liu, Hong Tao ^c   Stock, Wendy ^c   Godley, Lucy ^c   Odenike, Olatoyosi ^c   Larson, Richard ^c   Bishop, Michael ^c   Wickrema, Amittha ^c   Gergis, Usama ^a   Mayer, Sebastian ^a   Shore, Tsiporah ^a   Tsai, Stephanie ^a   Rhodes, Joanna ^a   Cushing, Melissa M ^a   Korman, Sandra ^b   Artz, Andrew ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; HLA ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; DOUBLE CORD TRANSPLANTATION; ENGRAFTMENT; FEMALE; HAPLO CORD TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; LOW ENERGY RADIATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; SINGLE CORD TRANSPLANTATION; SURGICAL MORTALITY; THROMBOCYTE; WHOLE BODY RADIATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; GENETICS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; RECURRENT DISEASE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE PROGRESSION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MORTALITY; NEUTROPHILS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

EID: 84964780475     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.138594     Document Type: Article

References (54)

1. Gluckman E, Ruggeri A, Volt F, et al. Milestones in umbilical cord blood transplantation. Br J Haematol. 2011;154(4):441-447.
2. Sanz J, Sanz MA, Saavedra S, et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2010;16(1):86-94.
3. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693-4699.
4. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351(22):2265-2275.
5. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115(9):1843-1849.
6. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLAmismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282-288.
7. Weisdorf D, Eapen M, Ruggeri A, et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant researcheurocord analysis. Biol Blood Marrow Transplant. 2014;20(6):816-822.
8. Peffault de Latour R, Brunstein CG, Porcher R, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2013;19(9): 1355-1360.
9. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653-660.
10. Wagner JE Jr, Eapen M, Kurtzberg J. Oneunit versus two-unit cord-blood transplantation. N Engl J Med. 2015;372(3):288-293.
11. Fernandez MN, Regidor C, Cabrera R, et al. Unrelated umbilical cord blood transplants in adults: Early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol. 2003;31(6):535-544.
12. Gormley NJ, Wilder J, Khuu H, et al. Co-Infusion of Allogeneic Cord Blood with Haploidentical CD34+ Cells Improved Transplant Outcome for Patients with Severe Aplastic Anemia Undergoing Cord Blood Transplantation. ASH Annual Meeting Abstracts. 2011;118:654.
13. Kwon M, Bautista G, Balsalobre P, et al. Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant. 2014;20:(12):2015-2022.
14. Liu H, van Besien K. Alternative donor transplantation-" mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors. Curr Hematol Malig Rep. 2015;10(1):1-7.
15. Lindemans CA, van Besien K. Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells. Cytotherapy. 2015;17(6):723-729.
16. Liu H, Rich ES, Godley L, et al. Reducedintensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118 (24):6438-6445.
17. Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012;119(23):5591-5598.
18. Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117(8): 2332-2339.
19. Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123(1):133-140.
20. Yoshihara S, Taniguchi K, Ogawa H, Saji H. The role of HLA antibodies in allogeneic SCT: is the type-and-screen strategy necessary not only for blood type but also for HLA? Bone Marrow Transplant. 2012;47(12):1499-1506.
21. Gergis U, Mayer S, Gordon B, et al. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014;49(5):722-724.
22. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
23. Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333-1338.
24. American Society of Blood and Marrow Transplantation. ASBMT RFI 2015 -Disease Classifications Corresponding to CIBMTR Classifications. Available from: http://c.ymcdn.com/sites/www.asbmt.org/resource/resmgr/RFI/RFI_2015_-_CIBMTR_Disease_Cl.pdf. Last accessed 22 March 2016.
25. Zhang X, Zhang MJ. SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed. 2011;101(1):87-93.
26. Zhang X, Loberiza FR, Klein JP, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed. 2007;88(2):95-101.
27. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110(8): 3064-3070.
28. van Besien K, Smith S, Anastasi J, et al. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004;103(11):4373-4374.
29. Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009;15(5):564-573.
30. Ramirez P, Brunstein CG, Miller B, Defor T, Weisdorf D. Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival. Bone Marrow Transplant. 2011;46(7):981-986.
31. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344(24):1815-1822.
32. Rio B, Chevret S, Vigouroux S, et al. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial. Biol Blood Marrow Transplant. 2015;21(3):445-453.
33. de Lima M, Anagnostopoulos A, Munsell M, et al. Non-Ablative versus Reduced Intensity Conditioning Regimens in the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Dose is Relevant for Long-Term Disease Control after Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2004;104(3):865-872.
34. Lindemans CA, te Boome LCJ, Admiraal R, et al. Sufficient Immune-suppression with Thymoglobulin is essential for a successful Haplo-myeloid Bridge in Haplo-Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015;21(19):1839-1845.
35. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-Tcell antibodies on the outcome of reducedintensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963-6970.
36. Segovia J, van Besien K. Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. Leuk Lymphoma. 2015;56(4):841-842.
37. Ophir E, Reisner Y. The use of donorderived veto cells in hematopoietic stem cell transplantation. Front Immunol. 2012;3:93.
38. Storb R, Gyurkocza B, Storer BE, et al. Graftversus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530-1538.
39. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784-3792.
40. Boyiadzis M, Arora M, Klein J, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2015;21(9):2020-2028.
41. Page KM, Mendizabal A, Betz-Stablein B, et al. Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality. Transfusion. 2014;54(2): 340-352.
42. Cairo MS, Wagner EL, Fraser J, et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion. 2005;45(6):856-866.
43. Joshua TV, Rizzo JD, Zhang MJ, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010;116(14):3469-3476.
44. Baker KS, Davies SM, Majhail NS, et al. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(12):1543-1554.
45. Schwake CJ, Eapen M, Lee SJ, et al. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biol Blood Marrow Transplant. 2005;11(12):988-998.
46. Blaes AH, Cao Q, Wagner JE, et al. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010;16(2):287-291.
47. Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114(19):4002-4008.
48. Baron F, Labopin M, Blaise D, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(3):389-396.
49. Salem G, Ruppert AS, Elder P, et al. Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2015;56(4):1058-1065.
50. Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilicalcord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12(13): 1214-1221.
51. Cutler C, Stevenson K, Kim HT, et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011;46(5):659-667.
52. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13(1):82-89.
53. van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, and Applications. Biol Blood Marrow Transplant. 2013;19(5):682-691.
54. Lund TC, Boitano AE, Delaney CS, Shpall EJ, Wagner JE. Advances in umbilical cord blood manipulation-from niche to bedside. Nat Rev Clin Oncol. 2015;12(3):163-174.